135La as an Auger-electron emitter for targeted internal radiotherapy

J. Fonslet, B. Q. Lee, T. A. Tran, M. Siragusa, M. Jensen, T. Kibédi, A. E. Stuchbery, G. W. Severin*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    22 Citations (Scopus)


    135La has favorable nuclear and chemical properties for Auger-based targeted internal radiotherapy. Here we present detailed investigations of the production, emissions, and dosimetry related to 135La therapy. 135La was produced by 16.5 MeV proton irradiation of metallic natBa on a medical cyclotron, and was isolated and purified by trap-and-release on weak cation-exchange resin. The average production rate was 407 19 MBq A-1 (saturation activity), and the radionuclidic purity was 98% at 20 h post irradiation. Chemical separation recovered > 98 % of the 135La with an effective molar activity of 70 20 GBq mol-1. To better assess cellular and organ dosimetry of this nuclide, we have calculated the x-ray and Auger emission spectra using a Monte Carlo model accounting for effects of multiple vacancies during the Auger cascade. The generated Auger spectrum was used to calculate cellular S-factors. 135La was produced with high specific activity, reactivity, radionuclidic purity, and yield. The emission spectrum and the dosimetry are favorable for internal radionuclide therapy.

    Original languageEnglish
    Article number015026
    JournalPhysics in Medicine and Biology
    Issue number1
    Publication statusPublished - Jan 2018


    Dive into the research topics of '135La as an Auger-electron emitter for targeted internal radiotherapy'. Together they form a unique fingerprint.

    Cite this